HyBryte™ use in early-stage cutaneous T-cell lymphoma

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Poligone, Brian
    • Other Affiliation: Rochester Skin Lymphoma Medical Group
  • Alexander-Savino, Carolina V.
    • Other Affiliation: Rochester Skin Lymphoma Medical Group
  • Kim, Ellen J.
    • Other Affiliation: University of Pennsylvania
  • Mangold, Aaron R.
    • Other Affiliation: Mayo Clinic Arizona
  • Desimone, Jennifer
    • Other Affiliation: Inova Schar Cancer Institute
  • Wong, Henry K.
    • Other Affiliation: University of Arkansas for Medical Sciences
  • Rumage, Adam T.
    • Other Affiliation: Soligenix, Inc
  • Donini, Oreola
    • Other Affiliation: Soligenix, Inc
  • Haulenbeek, Andrea
    • Other Affiliation: Soligenix, Inc
  • Schaber, Christopher J.
    • Other Affiliation: Soligenix, Inc
  • Straube, Richard
    • Other Affiliation: Soligenix, Inc
  • Pullion, Christopher
    • Other Affiliation: Soligenix, Inc
  • Rook, Alain H.
    • Other Affiliation: University of Pennsylvania
Abstract
  • Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma of the skin, where at later stages skin-homing malignant T-cells affect lymph nodes, blood, and visceral organs. Even though early CTCL does not affect survival, it can progress to more advanced stages of disease and have a significant effect on the quality of life of patients. Although expectant management is a treatment consideration in early disease stages, most patients cycle through different skin-directed therapies throughout their lifetime. It can become a challenge to manage the serious and accumulating risk of side effects of these therapies, including various skin cancers and skin damage. Adverse effects from topical therapies limit their long-term utility. Thus, there is an unmet need for well-characterized therapies that have a rapid onset of action and minimal long-term/cumulative side effect profile. Most recently, the results of a Phase 3 study of topical HyBryte™ as a potential treatment for CTCL demonstrated its efficacy and safety profile. This article summarizes what is known about HyBryte™, focuses on its mechanism of action, and highlights its effectiveness, safety, and tolerability in the context of other current FDA-approved topical therapies for CTCL.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 4.0 International
Journal title
  • Frontiers in Drug Discovery
Journal volume
  • 3
Language
  • English
Version
  • Publisher
ISSN
  • 2674-0338
Publisher
  • Frontiers Media

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details fddsv-03-1298453.pdf 2023-12-05 Public Download